Floatz logo

Tas-102

Stage IV Renal Cell Cancer

ExelixisunclassifiedPhase 3Active
BB
68/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
55/ 100
Competitive Position
95/ 100

Competitive context

2 Active assets in the Stage IV Renal Cell Cancer cohort.

Asset / SponsorPhaseRating
Cediranib
CCTU- Cancer Theme
Phase 3BB
FLUDEOXYGLUCOSE
Rahul Aggarwal
Phase 2BB
INTERFERON ALFA-2B
University of Aarhus
Phase 2BB
Vorinostat
Nabil Adra
Phase 2BB
gp100 antigen
National Cancer Institute (NCI)
Phase 2B

View all 12 →

Same molecule, other indications

Tas-102 is also rated in:

Stage IV Non-Small Cell Lung Cancer AJCC v7Dormant
BB
Indicative ·
68 / 100
View asset →
Recurrent Pancreatic CancerDormant
BB
Indicative ·
66 / 100
View asset →
Carcinoma, Islet CellDormant
BB
Indicative ·
66 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →